Neuroplast
Latest round
- Series B
Last raised
- Nov 2021
Total raised
- Undisclosed
Investors
- 4
About Neuroplast
V.V. is based in Geleen, Netherlands, and focuses on developing treatments for neurodegenerative conditions.000 mn.000 mn to support its initiatives.Neuroplast's primary offering revolves around its innovative Neuro-Cells® platform, which represents a pioneering approach in autologous stem cell therapy. This therapy is designed to address neurodegenerative conditions resulting from trauma, disease, and aging, specifically targeting injuries such as traumatic brain injury and spinal cord injury, as well as chronic conditions like Alzheimer’s and Parkinson’s diseases. The Neuro-Cells® technology utilizes the patient’s own cells to promote healing and regeneration in the nervous system, thereby providing personalized medical solutions. Neuroplast aims to serve a customer base that includes healthcare providers, research institutions, and potentially direct consumers seeking advanced treatment options for neurodegenerative impairments.Neuroplast's revenue model is structured around the provision of its Neuro-Cells® therapy, which involves direct transactions with healthcare providers and potentially participating in partnerships with medical institutions. The company engages in B2B transactions, supplying its innovative stem cell therapy to hospitals and specialized clinics that treat neurodegenerative conditions. The pricing structure is typically based on the complexity of the treatment and the required therapeutic protocols, with each therapy session tailored to the individual needs of the patient.V. This includes conducting Phase II and III trials, consulting with the EMA, and executing a Health Technology Assessment. Additionally, the company is targeting expansion into new markets, particularly across Europe and North America, where there is a significant prevalence of neurodegenerative conditions. The anticipated growth trajectory aligns with their commitment to advancing treatment options for affected patients.
Who invested in Neuroplast
4 investors across 1 round
See all investors in Neuroplast
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Nov 17, 2021
Amount
Undisclosed
Investors
Questions about Neuroplast
Who invested in Neuroplast?
Neuroplast has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Neuroplast raised?
Neuroplast has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Neuroplast last raise money?
Neuroplast's most recent round on record is a Series B, in Nov 2021.
What does Neuroplast do?
Neuroplast is a biotechnology company.
Where is Neuroplast headquartered?
Neuroplast is headquartered in Geleen, Netherlands.
Which VCs invest in companies like Neuroplast?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Neuroplast's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Neuroplast? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.